指南与共识肝病

评估药物性肝损伤的先进临床前模型:欧洲药物性肝损伤网络共识声明

Advanced preclinical models for evaluation of drug-induced liver injury - consensus statement by the European Drug-Induced Liver Injury Network [PRO-EURO-DILI-NET].
指南 / 共识 · J Hepatol · 2021-06-24

欧洲药物性肝损伤网络(EURO-DILI-NET)发布专家共识声明,指出药物性肝损伤(DILI)是急性肝衰竭和肝移植的重要原因,但现有临床前模型因人与动物间差异及缺乏能复现人类DILI复杂病理生理特征的模型而难以预测DILI。共识详述了对更真实人类化系统的要求,并讨论了对乙酰氨基酚(APAP)病理生理学、新兴体外和体内临床前模型及先进成像与计算技术,以期改善DILI临床结局的预测并指导未来药物安全性测试。

要点

  • DILI是西方社会急性肝衰竭和肝移植的主要原因之一,临床亟需有效疗法。
  • 现有动物和体外模型因种属差异及无法复现人类DILI复杂特征而预测能力有限。
  • 共识提出需发展更真实的人类化系统以评估肝毒性并指导药物安全性测试。

核心结论

  • 需要发展更真实的人类化临床前系统以改善DILI预测并指导未来药物安全性测试。
  • 对乙酰氨基酚(APAP)过量肝毒性机制在现有动物和体外模型中仍未完全阐明。

研究设计与样本

  • 欧洲药物性肝损伤网络(EURO-DILI-NET)背书的专家共识声明,基于对现有临床前模型局限性的分析提出建议。

主要发现

  • DILI是西方社会急性肝衰竭的主要原因之一,也是肝移植的主要指征之一。
  • 人类与动物DILI之间的不一致以及缺乏能忠实复现人类DILI复杂病理生理特征的模型,导致DILI预测困难。
  • APAP过量因全球广泛用作镇痛药而是急性肝衰竭的主要原因,其肝毒性机制尚未完全阐明。

关键数值与推荐

  • 共识详述了对更真实人类化系统的要求,以评估肝毒性并指导未来药物安全性测试。
  • 共识讨论了APAP病理生理学的主要参与因素、新兴体外和体内临床前模型以及先进成像和计算技术。

临床怎么用

  • 临床前药物肝毒性评估应关注更接近人类生理的模型系统,以提高DILI预测能力。
  • 未来药物安全性测试可结合先进成像和计算技术以改善DILI临床结局预测。

局限性

  • 原文未报告具体研究样本量、数值阈值或系统评价方法学细节。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Drug-induced liver injury (DILI) is a major cause of acute liver failure (ALF) and one of the leading indications for liver transplantation in Western societies. Given the wide use of both prescribed and over the counter drugs, DILI has become a major health issue for which there is a pressing need to find novel and effective therapies. Although significant progress has been made in understanding the molecular mechanisms underlying DILI, our incomplete knowledge of its pathogenesis and inability to predict DILI is largely due to both discordance between human and animal DILI in preclinical drug development and a lack of models that faithfully recapitulate complex pathophysiological features of human DILI. This is exemplified by the hepatotoxicity of acetaminophen (APAP) overdose, a major cause of ALF because of its extensive worldwide use as an analgesic. Despite intensive efforts utilising current animal and in vitro models, the mechanisms involved in the hepatotoxicity of APAP are still not fully understood. In this expert Consensus Statement, which is endorsed by the European Drug-Induced Liver Injury Network, we aim to facilitate and outline clinically impactful discoveries by detailing the requirements for more realistic human-based systems to assess hepatotoxicity and guide future drug safety testing. We present novel insights and discuss major players in APAP pathophysiology, and describe emerging in vitro and in vivo pre-clinical models, as well as advanced imaging and in silico technologies, which may improve prediction of clinical outcomes of DILI.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Fernandez-Checa JC, Bagnaninchi P, Ye H, et al. Advanced preclinical models for evaluation of drug-induced liver injury - consensus statement by the European Drug-Induced Liver Injury Network [PRO-EURO-DILI-NET]. J Hepatol. 2021. PMID: 34171436. doi:10.1016/j.jhep.2021.06.021

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。